HURA (TuHURA Biosciences) Change In Receivables: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HURA TuHURA Biosciences Inc HURA
12 GF Score
Price $2.17
! 1 Warning Sign
View Full Analysis

What is TuHURA Biosciences Change In Receivables?

TuHURA Biosciences HURA 12 Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates HURA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

TuHURA Biosciences's change in receivables for the quarter that ended in Mar. 2026 was $0.00 Mil. It means TuHURA Biosciences's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

TuHURA Biosciences's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means TuHURA Biosciences's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

TuHURA Biosciences's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TuHURA Biosciences's liquidation value for the three months ended in Mar. 2026 was $-0.22 Mil.

TuHURA Biosciences  (NAS:HURA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TuHURA Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, TuHURA Biosciences's accounts receivable are only considered to be worth 75% of book value:

TuHURA Biosciences's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6.298-6.515+0.75 * 0+0.5 * 0
=-0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences Change In Receivables Related Terms

TuHURA Biosciences Change In Receivables Historical Data

* Premium members only.

The historical data trend for TuHURA Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences Change In Receivables Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00 0.00

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HURA
12GF Score
TuHURA Biosciences Inc HURA
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TuHURA Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
TuHURA Biosciences (HURA) has a Change In Receivables of $0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TuHURA Biosciences and its competitors.
Is TuHURA Biosciences' Change In Receivables too high?
TuHURA Biosciences' current Change In Receivables is $0.00 Mil. Overall, TuHURA Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' Change In Receivables compare to CNTB and CUE?
TuHURA Biosciences' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TuHURA Biosciences and its competitors. TuHURA Biosciences's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (HURA) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. TuHURA Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For TuHURA Biosciences (HURA), the current Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TuHURA Biosciences Business Description

Other Exchanges PL3:Germany
Address 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
12GF Score

Get the complete analysis for HURA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.17
Price